harvoni

Gilead Sciences

  Federal officials say state Medicaid agencies may be going too far when it comes to restricting access to new hepatitis C drugs. Rhode Island, like many states, requires Medicaid patients to meet a list of criteria before doctors can prescribe them the new medications. But those criteria may be too restrictive.

Gilead Sciences

Woonsocket-based pharmacy giant CVS has signed a deal with drug maker Gilead to offer its hepatitis C drugs Sovaldi and Harvoni, exclusively, for treating hepatitis C.

The deal covers patients enrolled in drug benefit plans managed by CVS. And the news comes on the heels of AbbVie's announcement of a deal with CVS competitor Express Scripts, which will offer AbbVie's hepatitis C treatment, Viekira Pak, exclusively.

What’s the price of a human life? Many of us would say each life is priceless. But health economists sometimes have a number in mind.

Want to know what that number is?

In this part of our series “At the Crossroads: The Rise of Hepatitis C and The Fight To Stop It,” we'll tell you that - and more. We go beyond the high price of new hepatitis C drugs  to ask: how much is too much? And what the heck is a "quality adjusted life year" anyway?

Jake Harper / RIPR

This year marks the 25th anniversary of the discovery of the hepatitis C virus. Since then, people with hepatitis C have had limited – and not very effective – options for treatment.

Until now.

Revolutionary new treatments have hit the market in just the last few months. But they’re so expensive health insurers are balking at the price.

Part four of our series “At the Crossroads: The Rise of Hepatitis C and the Fight to Stop it” looks at the high cost of these new treatments and who’s paying for them.